Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Regulation of the Natriuretic Peptide System
NCT02269072Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of Testosterone TEPI patch in Hypogonadism (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Atrial natriuretic peptide levels at 8 weeks. Planned start Feb 2015; status: withdrawn.
02
Drugs
Testosterone TEPI patch
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NCT02269072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269072.